Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.11 – $99.75
1% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M | $6.6M | $9.9M | $10.2M | $14.4M | $10.5M | $9.8M | $0 |
| Cost of revenue | $1.5M | $1.7M | $4.0M | $3.7M | $6.6M | $4.4M | $3.3M | $140.0K |
| Gross profit | $11.0M | $4.9M | $6.0M | $6.5M | $7.8M | $6.1M | $6.5M | −$140.0K |
| Gross margin | 88.0% | 73.7% | 60.0% | 63.8% | 54.0% | 58.2% | 66.3% | — |
| R&D | $259.0K | $184.0K | $285.0K | $44.0K | $174.0K | $34.0K | $42.0K | $0 |
| Operating income | −$7.9M | −$9.4M | −$6.4M | −$8.9M | −$14.4M | −$4.1M | −$5.8M | −$7.6M |
| EBITDA | −$7.6M | −$9.3M | −$6.4M | −$8.7M | −$7.2M | −$4.1M | −$5.9M | −$7.4M |
| Net income | −$6.5M | −$9.7M | −$11.0M | −$5.8M | −$10.6M | −$9.6M | −$7.2M | −$22.1M |
| Net margin | -52.3% | -146.4% | -111.1% | -57.1% | -73.6% | -92.2% | -73.8% | — |
| EPS (diluted) | -112.83 | -118.73 | -77.11 | -36.82 | -70.72 | -27.73 | -0.51 | -3.80 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-1.90 | $-1.90–$-1.90 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds NBY.
No tracked institution reports a position in NBY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-09-30 | $0.8000 | 2025-09-29 |
| Execution date | Ratio |
|---|---|
| 2026-02-23 | 1-for-5reverse |
| 2024-05-31 | 1-for-35reverse |
| 2022-11-16 | 1-for-35reverse |
| 2015-12-21 | 1-for-25reverse |
No one on the platform has traded NBY yet.
| $4M |
| — |
| PMCBPharmaCyte Biotech, Inc. | $0.73 | -5.03% | $5M | — |
| QNRXQuoin Pharmaceuticals, Ltd. | $4.55 | +2.25% | $9M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.6× sales vs its 21.2× historical median P/S.
Fair value ≈ $26.22 · price $1.95 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.